Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
1.480
-0.100 (-6.33%)
Feb 26, 2026, 2:40 PM EST - Market open
Entera Bio Employees
As of September 30, 2025, Entera Bio had 22 total employees, including 20 full-time and 2 part-time employees. The number of employees increased by 2 or 10.00% compared to the same quarter last year.
Employees
22
Change
2
Growth
10.00%
Revenue / Employee
$5,636
Profits / Employee
-$490,045
Market Cap
67.87M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 22 | 2 | 10.00% | 20 | 2 |
| Jun 30, 2025 | 21 | 2 | 10.53% | 19 | 2 |
| Mar 31, 2025 | 20 | 1 | 5.26% | 18 | 2 |
| Dec 31, 2024 | 20 | 2 | 11.11% | 18 | 2 |
| Sep 30, 2024 | 20 | -1 | -4.76% | 18 | 2 |
| Jun 30, 2024 | 19 | -2 | -9.52% | 17 | 2 |
| Mar 31, 2024 | 19 | 1 | 5.56% | 17 | 2 |
| Dec 31, 2023 | 18 | 1 | 5.88% | 17 | 1 |
| Sep 30, 2023 | 21 | 2 | 10.53% | 19 | 2 |
| Jun 30, 2023 | 21 | -1 | -4.55% | 19 | 2 |
| Mar 31, 2023 | 18 | -3 | -14.29% | 18 | 0 |
| Dec 31, 2022 | 17 | -3 | -15.00% | 15 | 2 |
| Sep 30, 2022 | 19 | -4 | -17.39% | 19 | 0 |
| Jun 30, 2022 | 22 | 3 | 15.79% | 22 | 0 |
| Mar 31, 2022 | 21 | 2 | 10.53% | 21 | 0 |
| Dec 31, 2021 | 20 | 2 | 11.11% | 18 | 2 |
| Sep 30, 2021 | 23 | 4 | 21.05% | 23 | 0 |
| Jun 30, 2021 | 19 | 0 | - | 19 | 0 |
| Mar 31, 2021 | 19 | -2 | -9.52% | 19 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pliant Therapeutics | 171 |
| Adicet Bio | 152 |
| Seres Therapeutics | 103 |
| Fractyl Health | 101 |
| XBiotech | 88 |
| PolyPid | 60 |
| eXoZymes | 31 |
| MediciNova | 13 |
ENTX News
- 15 days ago - Entera Bio Announces Open Market Purchases of Company Stock by Board Members - GlobeNewsWire
- 17 days ago - Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones - GlobeNewsWire
- 2 months ago - Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA's Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation - GlobeNewsWire
- 2 months ago - Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program) - GlobeNewsWire
- 3 months ago - Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference - GlobeNewsWire
- 4 months ago - Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women - GlobeNewsWire
- 4 months ago - Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting - GlobeNewsWire
- 7 months ago - Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates - GlobeNewsWire